NASDAQ · Biotechnology

Ultragenyx Pharmaceutical Inc. (RARE) Stock

$15.48 +1.24% NASDAQ: RARE Healthcare

Valuation

MetricValue
Price$15.48
Market Cap$1.52B
P/E Ratio-2.55
P/B Ratio-5.21
P/S Ratio2.05
EPS (TTM)$-6.10
52-Week High$39.89
52-Week Low$12.73
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE392.35%
ROA-46.39%
ROCE-57.93%
Gross Margin-28.06%
Operating Margin-1.02%
Net Margin-81.79%
Debt/Equity-4.13
Current Ratio2.02

Annual Financials (USD)

Metric20212022202320242025
Revenue$351.0M$363.0M$434.0M$560.0M$673.0M
Operating Profit$-382.0M$-649.0M$-569.0M$-536.0M$-535.0M
Net Profit$-454.0M$-707.0M$-607.0M$-569.0M$-575.0M
EPS$-6.70$-10.12$-8.25$-6.29$-5.83
Op Margin-108.6%-178.6%-131.1%-95.7%-79.5%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$1.5B$1.5B$1.5B$1.5B$1.5B
Total Liabilities$600.0M$1.2B$1.2B$1.2B$1.6B
Cash$308.0M$133.0M$214.0M$174.0M$434.0M
Borrowings$42.0M$32.0M$43.0M$40.0M$1.3B

Latest News

Wedbush Raises Price Target on Ultragenyx Pharmaceutical to $30 From $26, Keeps Neutral Rating MT Newswires · Jul 13, 2026 Ultragenyx Releases 2025 Impact Report Emphasizing Commitment to Rare Disease Patients, Innovation, and Global Impact GlobeNewswire · Jul 8, 2026 IONS Completes Enrollment in Pivotal Cohort of Angelman Syndrome Study Zacks · Jul 7, 2026 RBC Capital Adjusts Ultragenyx Pharmaceutical Price Target to $40 From $35, Maintains Outperform Rating MT Newswires · Jul 7, 2026 Ultragenyx (RARE) Soars 5.2%: Is Further Upside Left in the Stock? Zacks · Jun 29, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-339.0M$-380.0M$-475.0M$-414.0M$-466.0M
Investing Cash Flow$-268.0M$-438.0M$121.0M$-25.0M$230.0M
Financing Cash Flow$40.0M$501.0M$8.0M$18.0M$0
Net Cash Flow$-417.0M$-172.0M$82.0M$-35.0M$253.0M
Free Cash Flow$-412.0M$-527.0M$-522.0M$-422.0M$-472.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.41
EV / EBITDA-5.38
FCF Yield-33.38%
Quick Ratio1.56
Interest Coverage-6.95
Return 1Y4.56%
Return 3Y-36.01%
Return 5Y-66.58%

Ownership

Insiders Held3.45%
Institutions Held101.90%
Institutions Float Held105.54%

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ABEOAbeona Therapeutics Inc. $4.94 -0.40% -4.43 $281.56M 0.00%
BBIOBridgeBio Pharma, Inc. $65.35 +0.48% -18.58 $12.80B 0.00%
BMRNBioMarin Pharmaceutical Inc. $54.80 -0.17% 151.42 $10.59B 0.00%
FDMT4D Molecular Therapeutics, Inc. $13.33 +4.96% -5.03 $696.84M 0.00%
MGTXMeiraGTx Holdings plc $10.69 +1.81% 17.43 $990.00M 0.00%

About Ultragenyx Pharmaceutical Inc.

Ultragenyx Pharmaceutical Inc. (RARE) stock trades at $15.48 with a market capitalization of $1.52B. The stock is valued at a price-to-earnings (P/E) ratio of -2.55, price-to-book of -5.21, price-to-sales of 2.05. Over the past 52 weeks the stock has ranged between $12.73 and $39.89, and currently trades 61.2% below its 52-week high.

On profitability, Ultragenyx Pharmaceutical Inc. generates a return on equity (ROE) of 392.35% — well above the market average, a sign of a high-quality business, return on capital employed of -57.93%, an operating margin of -1.02%, a net profit margin of -81.79%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.20 +0.26% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.64 +1.20%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides